R&G PharmaStudies Co (SZSE:301333) YoY EBITDA Growth : -15.13% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is R&G PharmaStudies Co YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. R&G PharmaStudies Co's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was -15.13%.

R&G PharmaStudies Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.29.

R&G PharmaStudies Co YoY EBITDA Growth Historical Data

The historical data trend for R&G PharmaStudies Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

R&G PharmaStudies Co YoY EBITDA Growth Chart

R&G PharmaStudies Co Annual Data

Trend

Dec13

Dec14

Dec15

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

508.17

-71.43

21.89

-4.72

39.25

R&G PharmaStudies Co Quarterly Data
	Dec17	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															-21.45	-21.89	42.77	43.34	-15.13

R&G PharmaStudies Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

R&G PharmaStudies Co's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(2.785	-	2)	/	\| 2 \|
=	39.25 %

R&G PharmaStudies Co's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(0.286	-	0.337)	/	\| 0.337 \|
=	-15.13 %

R&G PharmaStudies Co YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of R&G PharmaStudies Co's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

R&G PharmaStudies Co (SZSE:301333) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » R&G PharmaStudies Co Ltd (SZSE:301333) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 518, Chuangyi West Road, East District, Economic Development Zone, Tongzhou District, Beijing, CHN, 100048

Website

R&G PharmaStudies Co Ltd is a clinical trial outsourcing service provider. It offers full-chain clinical research outsourcing services, serving global pharmaceutical and medical device companies and scientific research institutions.

R&G PharmaStudies Co (SZSE:301333) Headlines

No Headlines